Literature DB >> 21964406

The monocrotaline model of pulmonary hypertension in perspective.

Jose G Gomez-Arroyo1, Laszlo Farkas, Aysar A Alhussaini, Daniela Farkas, Donatas Kraskauskas, Norbert F Voelkel, Harm J Bogaard.   

Abstract

Severe forms of pulmonary arterial hypertension (PAH) are characterized by various degrees of remodeling of the pulmonary arterial vessels, which increases the pulmonary vascular resistance and right ventricular afterload, thus contributing to the development of right ventricle dysfunction and failure. Recent years have seen advances in the understanding of the pathobiology of PAH; however, many important questions remain unanswered. Elucidating the pathobiology of PAH continues to be critical to design new effective therapeutic strategies, and appropriate animal models of PAH are necessary to achieve the task. Although the monocrotaline rat model of PAH has contributed to a better understanding of vascular remodeling in pulmonary hypertension, we question the validity of this model as a preclinically relevant model of severe plexogenic PAH. Here we review pertinent publications that either have been forgotten or ignored, and we reexamine the monocrotaline model in the context of human forms of PAH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21964406     DOI: 10.1152/ajplung.00212.2011

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  142 in total

Review 1.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 2.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

3.  Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Authors:  Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas
Journal:  Am J Respir Cell Mol Biol       Date:  2014-09       Impact factor: 6.914

4.  Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension.

Authors:  Benjamin Strauss; Yassine Sassi; Carlos Bueno-Beti; Zeki Ilkan; Nour Raad; Marine Cacheux; Malik Bisserier; Irene C Turnbull; Erik Kohlbrenner; Roger J Hajjar; Lahouaria Hadri; Fadi G Akar
Journal:  J Mol Cell Cardiol       Date:  2018-11-28       Impact factor: 5.000

5.  Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy.

Authors:  Masashi Ikutani; Koichi Tsuneyama; Makoto Kawaguchi; Junya Fukuoka; Fujimi Kudo; Susumu Nakae; Makoto Arita; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal:  JCI Insight       Date:  2017-04-06

6.  Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension.

Authors:  Zhiyuan Ma; Lan Mao; Sudarshan Rajagopal
Journal:  J Vis Exp       Date:  2016-04-11       Impact factor: 1.355

7.  Analysis of the microRNA signature driving adaptive right ventricular hypertrophy in an ovine model of congenital heart disease.

Authors:  Rebecca Johnson Kameny; Youping He; Terry Zhu; Wenhui Gong; Gary W Raff; Cheryl J Chapin; Sanjeev A Datar; Jason T Boehme; Akiko Hata; Jeffrey R Fineman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

8.  Rebuttal from Sally H. Vitali.

Authors:  Sally H Vitali
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

9.  Modafinil improves monocrotaline-induced pulmonary hypertension rat model.

Authors:  Hyeryon Lee; Kwan Chang Kim; Min-Sun Cho; Suk-Hyo Suh; Young Mi Hong
Journal:  Pediatr Res       Date:  2016-03-09       Impact factor: 3.756

10.  Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

Authors:  Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Eva Nozik-Grayck; Ivan F McMurtry; Masahiko Oka; Masanobu Komatsu; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.